|
1
|
DeSantis C, Siegel R, Bandi P and Jemal A:
Breast cancer statistics, 2011. CA Cancer J Clin. 61:409–418. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Solomayer EF, Diel IJ, Meyberg GC, Gollan
C and Bastert G: Metastatic breast cancer: Clinical course,
prognosis and therapy related to the first site of metastasis.
Breast Cancer Res Treat. 59:271–278. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Yan Q and Sage EH: SPARC, a matricellular
glycoprotein with important biological functions. J Histochem
Cytochem. 47:1495–1506. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Bellahcène A and Castronovo V: Increased
expression of osteonectin and osteopontin, two bone matrix
proteins, in human breast cancer. Am J Pathol. 146:95–100.
1995.PubMed/NCBI
|
|
5
|
Jacob K, Webber M, Benayahu D and Kleinman
HK: Osteonectin promotes prostate cancer cell migration and
invasion: A possible mechanism for metastasis to bone. Cancer Res.
59:4453–4457. 1999.PubMed/NCBI
|
|
6
|
De S, Chen J, Narizhneva NV, Heston W,
Brainard J, Sage EH and Byzova TV: Molecular pathway for cancer
metastasis to bone. J Biol Chem. 278:39044–39050. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Helleman J, Jansen MP, Ruigrok-Ritstier K,
van Staveren IL, Look MP, Meijer-van Gelder ME, Sieuwerts AM, Klijn
JG, Sleijfer S, Foekens JA and Berns EM: Association of an
extracellular matrix gene cluster with breast cancer prognosis and
endocrine therapy response. Clin Cancer Res. 14:5555–5564. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Hsiao YH, Lien HC, Hwa HL, Kuo WH, Chang
KJ and Hsieh FJ: SPARC (osteonectin) in breast tumors of different
histologic types and its role in the outcome of invasive ductal
carcinoma. Breast J. 16:305–308. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Koblinski JE, Kaplan-Singer BR, VanOsdol
SJ, Wu M, Engbring JA, Wang S, Goldsmith CM, Piper JT, Vostal JG,
Harms JF, et al: Endogenous osteonectin/SPARC/BM-40 expression
inhibits MDA-MB-231 breast cancer cell metastasis. Cancer Res.
65:7370–7377. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Ni X, Xia T, Zhao Y, Zhou W, Wu N, Liu X,
Ding Q, Zha X, Sha J and Wang S: Downregulation of miR-106b induced
breast cancer cell invasion and motility in association with
overexpression of matrix metalloproteinase 2. Cancer Sci.
105:18–25. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
van Nijnatten TJA, Moossdorff M, de Munck
L, Goorts B, Vane MLG, Keymeulen KBMI, Beets-Tan RGH, Lobbes MBI
and Smidt ML: TNM classification and the need for revision of pN3a
breast cancer. Eur J Cancer. 79:23–30. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Watkins G, Douglas-Jones A, Bryce R,
Mansel RE and Jiang WG: Increased levels of SPARC (osteonectin) in
human breast cancer tissues and its association with clinical
outcomes. Prostaglandins Leukot Essent Fatty Acids. 72:267–272.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Marshall MS: Ras target proteins in
eukaryotic cells. FASEB J. 9:1311–1318. 1995.PubMed/NCBI
|
|
15
|
Funk SE and Sage EH: The Ca2(+)-binding
glycoprotein SPARC modulates cell cycle progression in bovine
aortic endothelial cells. Proc Natl Acad Sci USA. 88:2648–2652.
1991. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Infante JR, Matsubayashi H, Sato N,
Tonascia J, Klein AP, Riall TA, Yeo C, Iacobuzio-Donahue C and
Goggins M: Peritumoral fibroblast SPARC expression and patient
outcome with resectable pancreatic adenocarcinoma. J Clin Oncol.
25:319–325. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Yamanaka M, Kanda K, Li NC, Fukumori T,
Oka N, Kanayama HO and Kagawa S: Analysis of the gene expression of
SPARC and its prognostic value for bladder cancer. J Urol.
166:2495–2499. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Iacobuzio-Donahue CA, Argani P, Hempen PM,
Jones J and Kern SE: The desmoplastic response to infiltrating
breast carcinoma: Gene expression at the site of primary invasion
and implications for comparisons between tumor types. Cancer Res.
62:5351–5357. 2002.PubMed/NCBI
|
|
19
|
Koukourakis MI, Giatromanolaki A, Brekken
RA, Sivridis E, Gatter KC, Harris AL and Sage EH: Enhanced
expression of SPARC/osteonectin in the tumor-associated stroma of
non-small cell lung cancer is correlated with markers of
hypoxia/acidity and with poor prognosis of patients. Cancer Res.
63:5376–5380. 2003.PubMed/NCBI
|
|
20
|
Sage H, Johnson C and Bornstein P:
Characterization of a novel serum albumin-binding glycoprotein
secreted by endothelial cells in culture. J Biol Chem.
259:3993–4007. 1984.PubMed/NCBI
|
|
21
|
Prada F, Benedetti LG, Bravo AI, Alvarez
MJ, Carbone C and Podhajcer OL: SPARC endogenous level, rather than
fibroblast-produced SPARC or stroma reorganization induced by
SPARC, is responsible for melanoma cell growth. J Invest Dermatol.
127:2618–2628. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Charest A, Pépin A, Shetty R, Côté C,
Voisine P, Dagenais F, Pibarot P and Mathieu P: Distribution of
SPARC during neovascularisation of degenerative aortic stenosis.
Heart. 92:1844–1849. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Lien HC, Hsiao YH, Lin YS, Yao YT, Juan
HF, Kuo WH, Hung MC, Chang KJ and Hsieh FJ: Molecular signatures of
metaplastic carcinoma of the breast by large-scale transcriptional
profiling: Identification of genes potentially related to
epithelial-mesenchymal transition. Oncogene. 26:7859–7871. 2007.
View Article : Google Scholar : PubMed/NCBI
|
